drugset / Trial / NCT00123669

Primary Progesterone Therapy for Operable Breast Cancer

NCT00123669 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. The study addresses two issues related to breast cancer surgery: * Circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer. * Events at the time of surgery may have an impact on the natural history of breast cancer

Timeline

Start
1997-10
Primary completion
2020-05-29
Completion
2020-05-29

Outcome

Missed primary endpoint

paper 5-year DFS and OS rates were 73.9% v 70.2% (hazard ratio [HR], 0.87; 95% CI, 0.68 to 1.09; P = .23) PMID 21670457 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject hydroxy-progesterone Unknown 500 mg Intramuscular

Indications